Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma (Q45712444)

15 December 2017

Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma (English)

1 reference

15 December 2017

1 reference

9

Dirk Schadendorf

1 reference

15 December 2017

5

Christine S Falk

1 reference

15 December 2017

Alexandra Sevko

1

1 reference

15 December 2017

Moshe Sade-Feldman

2

1 reference

15 December 2017

Julia Kanterman

3

1 reference

15 December 2017

Tillmann Michels

4

1 reference

15 December 2017

Ludmila Umansky

6

1 reference

15 December 2017

Marcel Ramacher

7

1 reference

15 December 2017

Masashi Kato

8

1 reference

15 December 2017

Michal Baniyash

10

1 reference

15 December 2017

Viktor Umansky

11

1 reference

15 December 2017

language of work or name

English

0 references

publication date

6 December 2012

1 reference

Journal of Investigative Dermatology

15 December 2017

1 reference

15 December 2017

133

1 reference

15 December 2017

1610-1619

1 reference

15 December 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2012.444

15 December 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Chronic inflammation, immunosuppression and cancer: new insights and outlook

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Recognition ligands on apoptotic cells: a perspective

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Clinical use of immunosuppressive drugs: part I

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

https://api.crossref.org/works/10.1038%2FJID.2012.444

1 reference

7 January 2021

Transgenic mouse model for skin malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Administration of cyclophosphamide changes the immune profile of tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Epidemiology of invasive cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Cancer-related inflammation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Myeloid-derived suppressor cells: linking inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Infection, immunoregulation, and cancer.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

A 'good death' for tumor immunology

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Humoral immunity, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

The anticancer immune response: indispensable for therapeutic success?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.444

7 January 2021

Identifiers

DOI

10.1038/JID.2012.444

1 reference

Dimensions Publication ID

15 December 2017

0 references

1 reference